Adicet Bio, Inc. Announces Closing of $98 Million Public Follow-On Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
January 25 2024 - 4:01PM
Business Wire
Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology
company discovering and developing allogeneic gamma delta T cell
therapies for autoimmune diseases and cancer, today announced the
closing of its previously announced underwritten public offering of
32,379,667 shares of its common stock, which includes 5,325,000
shares sold and issued upon the exercise in full by the
underwriters of their option to purchase additional shares of
common stock, and, in lieu of common stock to certain investors,
pre-funded warrants to purchase 8,445,333 shares of common stock.
The shares of common stock were sold at a public offering price of
$2.40 per share and the pre-funded warrants were sold at a public
offering price of $2.3999 per pre-funded warrant, which represents
the per share public offering price of each share of common stock
minus the $0.0001 per share exercise price for each pre-funded
warrant. The aggregate gross proceeds from the offering, before
deducting underwriting discounts and commissions and offering
expenses, were approximately $98.0 million. All of the securities
in the offering were sold by Adicet.
Jefferies and Guggenheim Securities acted as joint book-running
managers for the offering. Truist Securities also acted as a joint
bookrunner. Wedbush PacGrow and JMP Securities, A Citizens Company
acted as co-managers.
The securities described above were offered by Adicet pursuant
to a shelf registration statement that was previously filed with,
and subsequently declared effective on May 9, 2022 by, the U.S.
Securities and Exchange Commission (“SEC”). A final prospectus
supplement and accompanying prospectus relating to and describing
the terms of the offering was filed with the SEC on January 24,
2024. Copies of the final prospectus supplement and the
accompanying prospectus relating to the offered securities may be
obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus
Department, 520 Madison Avenue, New York, NY 10022, by telephone at
(877) 821-7388, or by email at prospectus_department@Jefferies.com
or Guggenheim Securities, LLC, Attention: Equity Syndicate
Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by
telephone at (212) 518-9544, or by email at
GSEquityProspectusDelivery@guggenheimpartners.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About Adicet
Adicet Bio, Inc. is a clinical stage biotechnology company
discovering and developing allogeneic gamma delta T cell therapies
for autoimmune diseases and cancer. Adicet is advancing a pipeline
of “off-the-shelf” gamma delta T cells, engineered with chimeric
antigen receptors (CARs), to facilitate durable activity in
patients.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240125334899/en/
Adicet Bio, Inc. Investor and Media Contacts Anne
Bowdidge abowdidge@adicetbio.com
Adicet Bio (NASDAQ:ACET)
Historical Stock Chart
From Sep 2024 to Oct 2024
Adicet Bio (NASDAQ:ACET)
Historical Stock Chart
From Oct 2023 to Oct 2024